This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OV101

Ovid Therapeutics, Inc.

Drug Names(s): MK-0928, 7-tetra hydroisoxazolo[5, 4-c]pyridin-3-ol (THIP)

Description: Gaboxadol is a selective extrasynaptic GABA(A) receptor agonist (SEGA) which enhances slow-wave sleep. It may act mainly at extrasynaptic GABA(A)alpha4betadelta receptors. Thus its effect is thought to be mediated via a GABA receptor population that is not modulated by benzodiazepines.

Deal Structure: Lundbeck and Merck
In February 2004, Lundbeck and Merck & Co. signed an agreement giving Merck the exclusive U.S. development and commercialization rights. Merck and Lundbeck will jointly complete the ongoing Phase III program, with Merck funding the majority of the remaining development activities. The parties anticipate that Merck will file an NDA with the U.S. FDA between late 2005 and mid 2007. Following FDA approval, the companies plan to co-promote gaboxadol in the U.S. Lundbeck will receive and initial payment of $70M USD and up to $200M USD in additional milestone payments prior to the launch of gaboxadol in the U.S. market.

Ovid and Lundbeck
In March 2015, H. Lundbeck and Ovid Therapeutics announced that they entered into an exclusive worldwide license agreement for gaboxadol. Under the terms of the agreement, Ovid obtained exclusive worldwide development and commercialization rights for OV101. In connection with the license, Lundbeck became a...See full deal structure in Biomedtracker

Partners: H. Lundbeck A/S


OV101 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug